CNS Response, Inc. Poster Session on Referenced-EEG(R) Guided Medication to Be Presented at the American Psychiatric Association 161st Annual Meeting
May 05, 2008
COSTA MESA, Calif., May 6 /PRNewswire-FirstCall/ -- CNS Response, Inc. CNSO announced today that Dr. James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs, will present a poster session at the American Psychiatric Association (APA) 161st Annual Meeting. The poster presentation, titled "Referenced-EEG Guided Medication Predictions in Treatment Refractory Eating Disorder Patients," will take place on Wednesday, May 7, 2008 from 3:00 p.m. to 5:00 p.m., ET.
The APA Annual Meeting will be held in Washington, DC from May 3-8, 2008. Further information on the conference can be found at www.psych.org.
About CNS Response
CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Contacts:
Investor Relations:
Sara Ephraim
(646) 536-7002
sephraim@theruthgroup.com
Media:
Jason Rando / Jennifer Saunders
(646) 536-7033 / 7011
jrando@theruthgroup.com
jsaunders@theruthgroup.com
Source: CNS Response, Inc.
Back to News and Press